Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | HTR1A | P08908 | 3/20 | 0.54 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.52 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 2/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7613022 | 0.99 | HTR7 (0.59) | HTR7KDM4ELMNAMAPK1HTR1A | |
| SCHEMBL6475395 | 0.87 | HTR1A (0.67) | HTR7LMNAHTR1AHTR2ADRD2 | |
| Hydrochloric Acid SCHEMBL7606820 | 0.86 | HTR1A (0.65) | HTR7LMNAMAPK1HTR1AHTR2A | |
| SCHEMBL6474706 | 0.84 | HTR7 (0.60) | HTR7KDM4ELMNAMAPK1HTR1A | |
| Hydrochloric Acid SCHEMBL7099309 | 0.83 | HTR7 (0.59) | HTR7KDM4ELMNAMAPK1HTR1A | |
| SCHEMBL6482761 | 0.83 | ADRA1B (0.55) | HTR7KDM4ELMNAMAPK1HTR1A | |
| SCHEMBL6474379 | 0.83 | MAPT (0.64) | HTR7HTR1AHTR2ADRD2 | |
| Hydrochloric Acid SCHEMBL7103130 | 0.82 | ADRA1B (0.56) | HTR7KDM4ELMNAMAPK1HTR1A | |
| Hydrochloric Acid SCHEMBL7605817 | 0.82 | MAPT (0.63) | HTR7HTR1AHTR2ADRD2 | |
| SCHEMBL6474033 | 0.81 | HTR7 (0.60) | HTR7KDM4EHTR1AHTR2ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020156085-A1 | 1,4-Disubstituted piperazine derivatives useful as uro-selective alpha1-adrenoceptor blockers | RANBAXY LABORATORIES LIMITED (IN) | 2002-10-24 | — | — | US | claimed |
| US-6914064-B2 | 1,4-Disubstituted piperazine derivatives useful as uro-selective α1-adrenoceptor blockers | RANBAXY LABORATORIES LIMITED (IN) | 2005-07-05 | — | — | US | disclosed |
| US-20020156085-A1 | 1,4-Disubstituted piperazine derivatives useful as uro-selective alpha1-adrenoceptor blockers | RANBAXY LABORATORIES LIMITED (IN) | 2002-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156085-A1 | 1,4-Disubstituted piperazine derivatives useful as uro-selective alpha1-adrenoceptor blockers | ADRB1, ADRB2, ADRA1B | HTR7 426/4885KDM4E 3522/4885LMNA 3477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.